中国肿瘤生物治疗杂志2017，Vol.24Issue(3)：300-304,5.DOI:10.3872/j.issn.1007-385X.2017.03.015
CIK细胞联合化疗治疗晚期胰腺癌临床疗效的回顾性分析
Retrospective analysis of clinical efficacy of CIK cells combined with chemotherapy for the patients with advanced pancreatic cancer
李瑞娥 1张勇 1王子兵 1尚艺曼 1杨勇豪 1王黎 1高全立1
作者信息
- 1. 郑州大学附属肿瘤医院生物免疫治疗科,河南郑州450008
- 折叠
摘要
Abstract
Objective:To analyze retrospectively the clinical efficacy and safety of the cytokine induced killer (CIK) cells combined with chemotherapy for the patients with advanced pancreatic carcinoma.Methods:Twenty eight patients with advanced pancreatic carcinoma who were hospitalized in Department of biotherapy,Tumor Hospital Affiliated to Zhengzhou University during September 2010 to February 2016 were collected.All of the patients received chemical treatment with gemcitabine and/or S-1.CIK cells cultured in vitro were transfused into the patients within 1 to 3 days after the chemotherapy.Rates of progressive disease (PD),stable disease (SD),partial regression (PR) and complete regression (CR),median overall survival (mOS),rates of survival for 6 months、12 months、18 months and 24 months,disease control rate (DCR) and adverse effects were observed.DCR included CR,PR and SD.Results:Among the 28 patients,PR rate 17.86％ (5 cases),SD rate 53.57％ (15 cases) and PD rate 28.57％ (8 cases) respectively.DCR was 71.43％.mOS was 15.41 months.Rates of survival for 6 months、12 months、18 months and 24 months respectively were 85.71％,50.00％,39.28％ and 10.71％.The major adverse effects were myelo suppression,nausea and emeses,which were improved after symptomatic treatments.Conclusion:The CIK cells combined with chemotherapy could be an effective and safety treatment approach for the patients with advanced pancreatic carcinoma.The patients might have little adverse reactions and well toleration.The treatment approach could markedly prolong survival of the patients.关键词
细胞因子诱导的杀伤细胞/胰腺癌/临床疗效Key words
cytokine-induced killer (CIK) cell/pancreatic carcinoma/clinical efficacy分类
医药卫生引用本文复制引用
李瑞娥,张勇,王子兵,尚艺曼,杨勇豪,王黎,高全立..CIK细胞联合化疗治疗晚期胰腺癌临床疗效的回顾性分析[J].中国肿瘤生物治疗杂志,2017,24(3):300-304,5.
